SAVA trade ideas
SAVA Double Bottom or Bull TrendHello,
What is SAVA?
We are a clinical-stage biopharmaceutical company focused on neuroscience. We translate novel scientific insights into new medicines. Our work is complex, risky, labor-intensive, persistent, and expensive. And it’s what we love to do. A key focus of our R&D is to develop first-in-class medicines for people with debilitating neurodegenerative conditions. In fact, Our mission is to detect and treat Alzheimer's disease. What if detecting Alzheimer’s was as simple as getting a blood test? We’re working on that too.
Let’s Shed Some Light on That Crash
Investing in micro-cap biotechs is a risky business. Although 2020 has seen a host of small biotech companies’ valuations soar on the back of promising trial data for a COVID-19 vaccine or treatment, it’s easy to forget just how devastating negative results can be. Bring results of a failed clinical trial to the public‘s attention, and the stock gets dropped faster than you can say “primary endpoint.”
Case in point: Cassava Sciences (SAVA). The Austin, Texas-based company shed 74% of its value in Friday’s session following the release of disappointing results from a Phase 2 study evaluating Cassava's lead investigational drug, PTI-125, in Alzheimer's disease (AD). The candidate failed to meet the primary endpoint, which was to produce a meaningful improvement in a number of AD biomarkers, when compared to the placebo.
Targeting an altered form of filamin A, a scaffolding protein present in the body, PTI-125 is a small molecule designed to reduce the protein’s effects. Present in the brains of AD patients, the extremely toxic form of the protein interferes with the normal function of neurons, thereby, causing neuroinflammation and neurodegeneration.
The company has noted that the high variability in biomarkers may have masked the drug’s effect, with it planning to further analyze the data. Although Maxim's Jason McCarthy notes there were positives to take away from the data, they are not enough to dissuade the analyst from changing his model for Cassava.
McCarthy said, “The data failed to meet the primary endpoint of significant improvement in AD biomarkers from baseline to Day 28 in treatment groups compared to placebo. A significant reduction in CSF levels, however, was noted in neuroinflammation biomarker IL1-beta, a secondary endpoint (p<0.035). Nonetheless, a miss is a miss and the path forward for PTI-125 is unclear.”
Accordingly, the analyst downgraded SAVA to Hold and removed the previous $12 price target “while the company further evaluates the data and path forward.” Only one other analyst has reviewed Cassava over the past three months, assigning the stock a Hold rating. Therefore, the micro-cap biotech has a Hold consensus rating.
Good Luck
Cheers!
Be sure to follow, like, and check my profile out for more trade ideas!
Cassava | Tomorrow - scheduled end of phase IIb | Jackpot?Is NASDAQ:SAVA about to blow up soon? The phase IIb will be most likely done by tomorrow whereby the analysis and evaluation of the results is scheduled for May. So there might be one last pullback before the stock will pulverize the last highs (in case the results are positive!). As a consequence of that I will look for good entries to ride the stock to at least 20$ per share :).
Cassava | Back in the game - giant bull flag!NASDAQ:SAVA has stopped it's decline at the 3$ floor and is now back in the giant bull flag.
Cassava | Giant bull flag | no time to panic!NASDAQ:SAVA it's not the time to panic now :). Just wait for the release of the phase IIb data which might blow up the flag in a sudden.
Cassava Science | Run for Alzheimer | Breakout soon?The price of NASDAQ:SAVA is forming a triangle whereby this formation is about to end very soon. Everyone is waiting for the results of the phase IIb study which will be reported in the mid of 2020. So the question is when the stock is going to break out of the low volatility phase. The first target for the upper side is 11$ which might be reached before the publication of the phase IIb results.
Cassava Sciences, Inc.ready for next bull run Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
SAVA bullish flag setting upSAVA bullish flag is setting up. This will take SAVA to the next level 16-20 level for consolidation.
Cassava Science | Run for Alzheimer | Upcoming breakout?The stock NASDAQ:SAVA is consolidating in a triangle and shows relative strength in the past few days. It might happen soon, that the stock will break through the upper boundary of the triangle which will lead the way towards 11$ and later also 15$.
Buy the dip in SAVA based on strong Alzheimer's trial dataCassava Sciences (SAVA) just got some positive clinical trial data on their Alzheimer’s drug. The result caused one analyst firm to upgrade SAVA’s price target from $3.00 per share to $6.00 per share. SAVA’s got a 9.4/10 analyst summary score, with most analysts rating the stock a “buy.” I entered SAVA Friday morning at $2.16 per share. It’s already up almost 100% from its share price last month, but I think it could continue its run next week.
SAVA - Above MA's Possible 15% TargetCassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
SHORT INTEREST
1.64M 08/30/19
P/E Current
-2.07
P/E Ratio (with extraordinary items)
-5.00
Average Recommendation: BUY
Average Target Price: 3.00
SAVAI hope the patter follows and we get news soon! Waiting to see it repeat the previous two spikes.
